The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab...
Noscendo, a leading provider of software-driven diagnostic solutions based on NGS (next-generation sequencing) that change the way infection-causing microbes are identifi...
Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone...
Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study
Demonstrated neutralizing capa...
Mireca’s proprietary cyclic guanosine monophosphate (cGMP) analogues to be developed using Graybug’s sustained-release drug delivery technologies
The partnership is exclusive for the development of p...
Strong preclinical evidence of universal efficacy of zapnometinib against coronavirus variants of concern
The findings underscore the importance of new therapeutic appro...
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation
Mul...
The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics
CureVac RNA Printer GmbH to provide dedicated infrastruct...
Preliminary data of first clinical studies show fast and reliable detection of active bleeding in the upper GI tract and the small intestine by the HemoPill acute. Substa...
Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains
Influenza candidate developed in collaboration ...
A case report describes the successful removal of a 22 mm non-granular laterally spreading across-fold lesion in the proximal colon with the EMR+ technique ...
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today ann...
The guideline recommends first-line OTSC therapy for esophageal perforation 1 – 2 cm in size, gastric perforations 1 – 3 cm in size, <13 mm type 1 duodenal perforations and certain colonic perforat...
FDA Orphan Drug Designation (ODD) underscores strength of Atriva’s pipeline and high need for treatments for rare and neglected tropical diseases
ODD allows Atriva to be...
AI research consortium celebrates anniversary
December is a special month for Cyber Valley: five years ago, the research consortium was founded in the Stuttgart-Tübingen region. As an internationally renowned hotspot for artificial intelligence...
Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-p...
Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva’s advisory board, bringing vast experience in late-stage pharmaceutical development
Frans van Dalen, Pharm D., representative of Atri...
Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation p...
